Cargando…

α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results

PURPOSE: We compared the effects of alpha-adrenergic receptor blocker (α-blocker) monotherapy with those of combination therapy with α-blocker and 5-alpha-reductase inhibitor (5-ARI) on benign prostatic hyperplasia (BPH) progression for over 10 years. MATERIALS AND METHODS: A total of 620 patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shin, Teak Jun, Kim, Chun Il, Park, Choal Hee, Kim, Byung Hoon, Kwon, Young Kee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332135/ https://www.ncbi.nlm.nih.gov/pubmed/22536467 http://dx.doi.org/10.4111/kju.2012.53.4.248

Ejemplares similares

Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia
por: Kim, Hyoung Woo, et al.
Publicado: (2011)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia
por: Hong, Kyoung Pyo, et al.
Publicado: (2010)

Ramelteon combined with an α(1)-blocker decreases nocturia in men with benign prostatic hyperplasia
por: Kawahara, Takashi, et al.
Publicado: (2013)

Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication
por: Ong, Hueih Ling, et al.
Publicado: (2016)

α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines
por: Xu, Xiao-Feng, et al.
Publicado: (2020)

Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia
por: Moon, Hyong Woo, et al.
Publicado: (2018)

5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data
por: Del Giudice, Francesco, et al.
Publicado: (2023)

Personalized therapeutics of α(1)-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
por: Zhu, Ling-ling, et al.
Publicado: (2015)

Long-Term Effect of Loxoprofen Sodium on Nocturia in Patients with Benign Prostatic Hyperplasia
por: Shin, Hong Il, et al.
Publicado: (2011)

Electronic medical records-based retrospective, longitudinal, observational study to understand the patient management of benign prostatic hyperplasia with alpha-blockers monotherapy in Indian population
por: Gupta, Rahul, et al.
Publicado: (2023)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
por: Kim, Jae Heon, et al.
Publicado: (2018)

Alpha-1 blockers and susceptibility to COVID-19 in benign prostate hyperplasia patients : an international cohort study
por: Nishimura, Akihiko, et al.
Publicado: (2021)

Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With α(1)-Blockers
por: Kobayashi, Minoru, et al.
Publicado: (2017)

A Meta-Analysis of Long- Versus Short-Acting Phosphodiesterase 5 Inhibitors: Comparing Combination Use With α-Blockers and α-Blocker Monotherapy for Lower Urinary Tract Symptoms and Erectile Dysfunction
por: Choi, Hoon, et al.
Publicado: (2015)

Add-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats
por: Ko, Il-Gyu, et al.
Publicado: (2018)

Efficacy of Alpha Blocker Treatment According to the Degree of Intravesical Prostatic Protrusion Detected by Transrectal Ultrasonography in Patients with Benign Prostatic Hyperplasia
por: Park, Hee Young, et al.
Publicado: (2012)

A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia
por: Nickel, J C, et al.
Publicado: (2008)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
por: Kim, Eric H., et al.
Publicado: (2018)

Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study
por: Kwon, Se Yun, et al.
Publicado: (2020)

Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis
por: Gwon, Yong Nam, et al.
Publicado: (2023)

Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study
por: Takahashi, Hiroshi, et al.
Publicado: (2019)

Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy
por: Cai, Tong, et al.
Publicado: (2020)

International cohort study indicates no association between alpha-1 blockers and susceptibility to COVID-19 in benign prostatic hyperplasia patients
por: Nishimura, Akihiko, et al.
Publicado: (2022)

Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis
por: Kim, Hyun Jung, et al.
Publicado: (2017)

Corni Fructus attenuates testosterone-induced benign prostatic hyperplasia by suppressing 5α-reductase and androgen receptor expression in rats
por: Hwangbo, Hyun, et al.
Publicado: (2018)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

Effectiveness and safety of electroacupuncture and its cotreatment with electronic moxibustion in the treatment of patients with moderate benign prostatic hyperplasia using alpha blocker: Study protocol for an assessor-blinded, randomized controlled clinical trial
por: Kim, Hyo Bin, et al.
Publicado: (2020)

Cyclooxygenase-2 Overexpression in Chronic Inflammation Associated with Benign Prostatic Hyperplasia: Is It Related to Apoptosis and Angiogenesis of Prostate Cancer?
por: Kim, Byung Hoon, et al.
Publicado: (2011)

Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
por: Shum, Cheuk Fan, et al.
Publicado: (2017)

Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia
por: Cho, Kang Jun, et al.
Publicado: (2011)

CNS Demyelination with TNF-α Blockers
por: Kemanetzoglou, Elissavet, et al.
Publicado: (2017)

Effect of α-receptor blockers on lower urinary tract symptoms, sexual function and quality of life in young and middle-aged men with benign prostatic hyperplasia
por: Wang, Tongqing, et al.
Publicado: (2017)

Depression risk associated with the use of 5α-reductase inhibitors versus α-blockers: A retrospective cohort study in South Korea
por: Yeon, Bora, et al.
Publicado: (2022)

Alpha–blocker and apoptosis
por: Elterman, Dean S., et al.
Publicado: (2013)

Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan
por: Masumori, Naoya, et al.
Publicado: (2016)

Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Is prostatic artery embolization a relevant treatment after a failed alpha-blocker monotherapy?
por: Lebdai, Souhil
Publicado: (2023)

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia
por: Kim, Won, et al.
Publicado: (2014)

A prospective pilotstudy comparing the anesthetic effects of an alpha-2 agonist during holmium laser resection of the prostate and transurethral resection for prostate surgery for benign prostatic hyperplasia patients using selective alpha-1 blockers
por: Lee, Do-Won, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kfucqqrb4ommql1k8uns7pghj8